Clinical Trials Arena on MSN

MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
The Lancet

Seema Sahay—linking behavioural science and HIV research

Today, Seema Sahay is Head of Division of Social Behavioural Research at the Indian Council of Medical Research, National Institute of Translational Virology & AIDS Research (NARI), Pune, India.

Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Rutgers University

Medicaid Expansion Increases Access to HIV Prevention Medication for High-Risk Populations

Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...
P.M. News on MSN

What Bishop Abioye really meant in his so-called 'HIV' testimony

Bishop David Abioye has clarified a statement he made during a recent sermon, explaining that his wife was diagnosed with COVID-19, not HIV, as widely circulated on social media.The cleric, who leads ...
Opinion

The government has reopened, but Congress must protect HIV funding for 2026

Congress’s bipartisan agreement to end the government shutdown restores operations across the federal government, but keeps major health programs, including the nation’s HIV response, ...